Modulating donor mitochondrial fusion/fission delivers immunoprotective effects in cardiac transplantation

Danh T. Tran1,2 | Zhenxiao Tu1 | Ali Alawieh1 | Jennifer Mulligan3 | Scott Esckilsen2 | Kristen Quinn2 | Kamala Sundararaj2 | Caroline Wallace2 | Ryan Finnegan2 | Patterson Allen2 | Shikhar Mehrotra2 | Carl Atkinson1,2,4 | Satish N. Nadig1,2,4

1Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina
2Department of Surgery, Division of Transplant Surgery, Lee Patterson Allen Transplant Immunobiology Laboratory, Medical University of South Carolina, Charleston, South Carolina
3Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, South Carolina
4South Carolina Investigators in Transplantation, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina

Correspondence
Satish N. Nadig, 96 Jonathan Lucas Street, MSC 613, CSB 409, Charleston, SC 29425, USA.
Email: satish.nadig@northwestern.edu

Funding information
This study was supported by grants from the National Institute of Health (NIH), R01 AI142079 01A1 to Dr. Satish Nadig, 1U01AI32984-01 to Dr. Carl Atkinson, NHLBI Predoctoral Fellowship Training Grant T32 HL007260 to Danh Tran, NIGMS MSTP Predoctoral Fellowship Training Grant T32 GM008716 to Danh Tran, funding from the Patterson Barclay Memorial Foundation, and funding grant USPHS S10 OD018113 “Confocal/Multiphoton Microscope Upgrade” to MUSC Imaging Core.

Early insults associated with cardiac transplantation increase the immunogenicity of donor microvascular endothelial cells (ECs), which interact with recipient alloreactive memory T cells and promote responses leading to allograft rejection. Thus, modulating EC immunogenicity could potentially alter T cell responses. Recent studies have shown modulating mitochondrial fusion/fission alters immune cell phenotype. Here, we assess whether modulating mitochondrial fusion/fission reduces EC immunogenicity and alters EC-T cell interactions. By knocking down DRP1, a mitochondrial fission protein, or by using the small molecules M1, a fusion promoter, and Mdivi1, a fission inhibitor, we demonstrate that promoting mitochondrial fusion reduced EC immunogenicity to allogeneic CD8+ T cells, shown by decreased T cell cytotoxic proteins, decreased EC VCAM-1, MHC-I expression, and increased PD-L1 expression. Co-cultured T cells also displayed decreased memory frequencies and Ki-67 proliferative index. For in vivo significance, we used a novel murine brain-dead donor transplant model. Balb/c hearts pretreated with M1/Mdivi1 after brain-death induction were heterotopically transplanted into C57BL/6 recipients. We demonstrate that, in line with our in vitro studies, M1/Mdivi1 pretreatment protected cardiac allografts from injury, decreased infiltrating T cell production of cytotoxic proteins, and prolonged allograft survival. Collectively, our data show promoting mitochondrial fusion in donor ECs mitigates recipient T cell responses and leads to significantly improved cardiac transplant survival.

KEYWORDS
animal models: murine, basic (laboratory) research/science, heart transplantation/cardiology, immunobiology, immunosuppression/immune modulation, ischemia reperfusion injury (IRI), rejection: acute, rejection: T cell mediated (TCMR), translational research/science

Abbreviations: BD, brain death; CS, cold storage; CS-IRI, cold storage-ischemia reperfusion injury; DRP1, dynamin-related protein 1; DRP1KD, dynamin-related protein 1 knock-down cell; EC, endothelial cell; IRI, ischemia-reperfusion injury; MCEC, microvascular cardiac endothelial cell; mPTP, mitochondrial permeability transition pore; MUSC, Medical University of South Carolina; NAC, N-acetylcysteine; Tmems, memory T cells; UW solution, University of Wisconsin solution; VDAC-1, voltage-dependent anion channel-1.
1 | INTRODUCTION

Despite the steady advancement of cardiac transplantation, long-term survival has not significantly improved due to early factors in the transplant process.1–3 Donor brain death (BD) activates multiple immunological components and predisposes a cardiac allograft to pro-inflammation.4–6 Subsequently, cold storage (CS) and ischemia-reperfusion injury (IRI) further exacerbate the heightened immunogenicity of the allograft.7 Sitting at the interface between the donor allograft and the recipient immune system are donor endothelial cells (ECs), which play a central role in an allograft’s immunogenicity as semi-professional antigen-presenting cells.8 Early injuries induced by BD, CS, and IRI activate and prime these cells to be immunogenic. Upon allograft implantation and reperfusion, ECs interact with recipient circulating alloreactive memory T cells (T mems) which subsequently infiltrate the cardiac allograft and mediate allograft rejection.9–15

Current standard-of-care immunosuppression prevents activation of naïve T cells but has minimal impact on T mems, and thus T mems are a barrier to transplant tolerance.16–18 Since T mems interact directly with ECs,11 modulating the immunogenicity of donor ECs early in the transplant process could potentially reduce alloreactive T mems responses. Also, treating a cardiac allograft prior to recipient implantation could potentially minimize side effects in the recipient.

Several studies have shown an important link between mitochondrial dysregulation and allograft rejection.19–26 Mitochondrial fusion/fission plays an important role in regulating mitochondrial fitness and cellular health. Fusion is mediated by several key machinery proteins, including mitofusin-1, mitofusin-2, and optic atrophy-1. Fission, on the other hand, is mediated by dynamin-related protein 1 (DRP1) and other accessory proteins.27,28 In transplantation, CS-IRI affects expression and processing of fusion/fission machinery proteins, leading to mitochondrial injury and impaired graft function.29 However, whether these alterations in donor graft mitochondrial fusion/fission has an impact on immunological outcomes remains unknown.

In non-transplant settings, mitochondrial fusion/fission has been shown to regulate immune cell phenotype, including dendritic cell differentiation and migration,30 and effector-memory functional transformation in T cells.31 Yet, whether mitochondrial fusion/fission regulates the immunological phenotype of ECs has not been reported. Furthermore, in the heart, modulating mitochondrial fusion/fission exhibits protective effects against focal IRI. In myocardial infarction mouse models, inhibiting mitochondrial fission stabilizes the cardiac microvasculature, maintains an intact endothelial barrier, and protects mitochondrial membrane potentials of ECs.32–34 Yet, whether inhibiting mitochondrial fission/promoting mitochondrial fusion provides protection against injury in transplant has not been investigated.

We have previously shown that modulating mitochondrial bioenergetics in ECs reduces their immunogenicity and leads to a favorable T cell response.35 Based on these observations, we hypothesized that modulating mitochondrial fusion/fission in donor ECs will provide protection from IRI and promote an EC immunological phenotype that decreases T mems responses. In this study, using in vitro and in vivo models, we promote mitochondrial fusion/inhibit mitochondrial fission in donor ECs and assess the impact on EC-T cell interactions and subsequent cardiac transplant outcomes.

2 | MATERIALS AND METHODS

2.1 | Animals

Male Balb/c and C57BL/6 mice, 8–12 weeks old (Jackson Laboratory, Bar Harbor, ME), were used for all co-culture and in vivo experiments. Mice were housed under conventional conditions at Medical University of South Carolina (MUSC, Charleston, SC). All procedures were performed accordingly to animal protocols approved by MUSC Committee for Animal Research in accordance with the NIH Guide for Care and Use of Laboratory Animals.

2.2 | Additional materials and methods

Details regarding cell lines and culture media, pharmacologic agents, confocal imaging, antibodies for immunoblotting and flow cytometry, oxygen consumption assay, memory CD8+ T cells generation and EC-T-cell co-culture, CS and warm reperfusion model, normothermic activation model, live/dead cell staining and counting, brain-death induction and heterotopic heart transplantation, primary cell isolation, transmission electron microscopy, trans-endothelial electrical resistance assays, cardiac injury assessment, histological analysis, and statistical analysis can be found in the online Supporting Information.

3 | RESULTS

3.1 | Genetic alteration of mitochondrial fission machinery reduces cardiac microvascular EC immunogenicity

With previous reports indicating that inhibiting mitochondrial fission to promote fusion can modulate the immunological phenotypes of T cells and mast cells,31,36 we reasoned that inhibiting mitochondrial fission in ECs would alter their immunogenicity. To determine the impact of mitochondrial fission inhibition in ECs, we generated DRP1 knock-down cells (DRP1KDs) by stably transfecting mouse microvascular cardiac endothelial cells (MCECs) with shRNAi plasmid, and subsequently maintained selection media. Fission machinery knock-down was validated by DRP1KD mitochondrial morphology imaging, which revealed significant elongation of the mitochondria as compared to wildtype MCECs (Figure 1A). Additionally, DRP1 levels in DRP1KDs were reduced compared to wildtype MCECs, as determined by Western blotting (Figure S1). To determine what
Genetic alteration of mitochondrial fission machinery reduces EC immunogenicity. (A) Representative 3D confocal images showing mitochondrial elongation in ECs that have dynamin-related protein 1 (DRP1) knocked down (referred to as DRP1KDs) (red: mitochondria, blue: nuclei), and quantification of mitochondrial morphology in cells (hyperfused: at least one mitochondria ≥5 μm in length, intermediate: at least one mitochondria between 5 and 2 μm but none more than 5 μm, rounded: none longer than 2 μm) (n = 4 with 80 cells/group). (B) Mitochondrial mass of DRP1KD versus MCEC (the wildtype control) quantified by flow cytometry for mean fluorescence intensity of Mitotracker Green (n = 3). (C) Mitochondrial fitness of DRP1KD versus MCEC assessed by Seahorse flux assay (n = 4). (D) Immunogenicity of DRP1KD versus MCEC when being co-cultured with allogeneic CD8⁺ T cells, demonstrated by supernatant levels of interferon gamma and granzyme-B levels after 7 days of coculturing (n = 3). (E) Representative 3D confocal images showing mitochondrial elongation is unchanged at 1 h post-reperfusion in DRP1KDs that were subjected to static cold storage for 6 h prior to reperfusion with warm media (red: mitochondria, blue: nuclei), and quantification of mitochondrial morphology performed as in Figure 1A (n = 4 with 80 cells/group). (F) Immunogenicity of DRP1KD versus MCEC that were subjected to cold storage for 6 h prior to reperfusion with warm media and co-cultured with allogeneic CD8⁺ T cells, demonstrated by supernatant levels of interferon gamma and granzyme-B after 7 days of coculturing (n = 3). (* * * * p < .0001, ** * p < .005, * * p < .01, * p < .05. Differences between DRP1KD versus MCEC were analyzed using Student’s t-test. In panels D and F, granzyme-B and interferon gamma levels were normalized to the number of ECs at the initiation of co-culture to account for target differences.)
other impact DRP1 knock-down had on the mitochondria, we assessed mitochondrial mass of DRP1 KDs, with Mitotracker Green as previously described. Inhibiting fission was known to increase mitochondrial mass in immune cells, and consistent with this study, we found that DRP1 KDs had a significantly increase in mitochondrial mass compared to wildtype MCECs (Figure 1B). To determine whether these mitochondrial structural changes affected function, we utilized Seahorse bioenergetic flux assays and demonstrated that mitochondrial fitness, represented by spare respiratory capacity, in DRP1 KDs was significantly increased as compared to wildtype controls (Figure 1C).

We next sought to determine whether knocking down DRP1 altered EC immunogenicity, and specifically whether these changes altered EC-T-cell interactions. We utilized a previously reported EC-T cell co-culture system in which T cells were procured from mice that had been pre-sensitized to donor ECs, thus recapitulating the in vivo scenario of pre-sensitized T cells. We have shown that co-cultures using T cells from non-sensitized animals showed little to no alloreactivity (Figure S2). Using this normothermic co-culture model with pre-sensitized allogeneic CD8+ T cells, in which DRP1 KDs or wildtype MCECs were co-cultured with CD8+ T cells for 7 days, DRP1 knock-down was associated with a marked reduction in secretion of IFNγ and granzyme-B (Figure 1D). In the clinical setting, cold storage-ischemia reperfusion injury (CS-IRI) associated with cardiac hypothermic preservation exacerbates EC immunogenicity. Thus, we subsequently examined whether an EC immunogenicity reduction would be similarly observed in the setting of hypothermic preservation. Using a clinically relevant CS-IRI model described previously, we first assessed DRP1 KD mitochondrial morphology at 1 h post-reperfusion following CS in UW solution, and found mitochondrial morphology was unaltered by CS (Figure 1E). To dissect the impact of EC immunogenicity, after 6 h of CS and upon reperfusion, DRP1 KDs or wildtype MCECs were co-cultured with pre-sensitized allogeneic CD8+ T cells for 7 days, as described above. In keeping with our normothermic data, IFNγ and granzyme-B were significantly reduced in DRP1 KD versus wildtype MCEC co-cultures (Figure 1F).

### 3.2 Pharmacological modulation of mitochondrial fusion/fission prior to pro-inflammatory cytokine insult reduces EC immunogenicity

For clinical relevance, we determined whether pharmacological modulation of mitochondria in MCECs could recapitulate outcomes seen in DRP1 KDs. Here, MCEC mitochondrial fusion was forced using M1, a mitochondrial fusion promoter, and Mdivi1, a mitochondrial fission inhibitor that blocks the self-assembly of DRP1. This combination has been reported to maximally skew mitochondrial fusion/fission toward fusion. When MCECs were treated with M1/Mdivi1 for 24 h, mitochondria were significantly elongated compared to untreated controls, as determined by confocal microscopy analysis (Figure 2A). To similarly determine the impact of mitochondrial therapy on MCEC immunogenicity, we repeated the co-culture experiments with pre-sensitized allogeneic CD8+ T cells. In keeping with our DRP1 KD data, secretion of IFNγ and granzyme-B were significantly decreased in co-cultures where MCECs were pretreated with M1/Mdivi1 compared to untreated controls (Figure 2B).

In the clinical setting, IRI promotes the secretion of pro-inflammatory cytokines by innate immune cells, and within this pro-inflammatory microenvironment, ECs are activated to become immunogenic. To investigate whether promoting fusion/inhibiting fission prior to such pro-inflammatory cytokine insult could prevent EC immunogenicity, we pretreated MCECs with M1/Mdivi1, activated them with TNFα/IFNγ, and performed flow cytometry for EC surface markers (gating strategy and live/dead staining shown in Figure S3A). While M1/Mdivi1 treatment induced no changes when cells were in their resting state, pre-treating cells with the mitochondrial drugs prior to TNFα/IFNγ activation reduced surface expression of the adhesion molecules VCAM-1 and ICAM-1 compared to untreated controls (Figure 2C). Other EC activation and T cell inhibition markers, including P-selectin, CD80, PD-L1 did not show any discernable differences following TNFα/IFNγ activation. Given these basal data, we next determined whether T cell co-culture altered EC activation markers after 4 days co-cultured with allogeneic CD8+ T cells. We found that PD-L1 was significantly up-regulated in the M1/Mdivi1-pretreated MCECs compared to the untreated controls (Figure 2C). Since PD-L1 inhibits T cell function, we investigated whether PD-L1 expression changes were responsible for the observed inhibition of T cell activity. Using our co-culture model, M1/Mdivi1-pretreated MCECs were co-incubated with allogeneic CD8+ T cells in the presence of anti-PD-L1 blocking antibodies, which resulted in the previously observed effect being partially abrogated (Figure 2D).

### 3.3 Pharmacological modulation of mitochondrial fusion/fission prior to cold storage reduces EC immunogenicity after reperfusion

As M1/Mdivi1 pre-treatment reduced EC immunogenicity to allogeneic T cells, we next investigated whether the same effects could be observed, for clinical translational relevance, in a CS-IRI setting. In this clinically relevant model, we pretreated MCECs with M1/Mdivi1 for 6 h in warm culture media, withdrew the drugs, then subjected the cells to CS-IRI. As a means of validation, at 1-h post-reperfusion, we imaged MCEC mitochondria and found that mitochondria in M1/Mdivi1-pretreated cells retained an elongated morphology compared to CS controls (i.e., untreated cells undergoing CS-IRI) (Figure 3A). To assess immunogenicity, upon reperfusion, we co-incubated M1/Mdivi1-pretreated MCECs or untreated controls with pre-sensitized allogeneic CD8+ T cells for 7 days. At the end of the co-culture, we found the levels of secreted IFNγ and granzyme-B were significantly reduced in pretreated cells compared to untreated controls (Figure 3B). Of note, IFNγ and granzyme-B...
FIGURE 2 Pharmacological modulation of mitochondrial fusion/fission prior to pro-inflammatory cytokine insult reduces EC immunogenicity. (A) Representative 3D confocal images showing mitochondrial elongation in M1/Mdivi1-treated MCECs (red: mitochondria, blue: nucleus), and quantification of mitochondrial morphology performed as in Figure 1A (n = 4 with 80 cells/group). (B) Immunogenicity of M1/Mdivi1-pretreated cells versus untreated control co-cultured with allogeneic CD8\(^+\) T cells, demonstrated by supernatant interferon gamma and granzyme-B levels after 7 days of coculturing (n = 3). (C) VCAM-1, ICAM-1 adhesion molecules expression on the surface of MCECs pretreated with M1/Mdivi1 for 24 h versus untreated control prior to activation by TNF\(\alpha\)/IFN\(\gamma\) (n = 4). (D) Abrogation of tolerogenic effect induced by M1/Mdivi1 when PD-L1 is blocked, demonstrated by supernatant interferon gamma and granzyme-B levels after 7 days of co-culturing in the presence of anti-PD-L1 blocking antibodies (n = 3). (*\(p < .05\), **\(p < .01\), ***\(p < .005\), ****\(p < .0001\)). Differences between untreated control and M1/Mdivi1-treated groups, as well as between PD-L1-unblocked control and PD-L1-blocked groups, were analyzed using Student’s t-test. In panels B and D, granzyme-B and interferon gamma levels were normalized to the number of ECs at the initiation of co-culture to account for target differences.
levels in the control groups in the more translationally relevant CS-IRI model were higher, as compared to those in the control groups of the normothermic cytokine-insult model. Yet, M1/Mdivi1 EC pretreatment still significantly reduced IFNγ and granzyme-B secretion by T cells to similar extents (Figures 2B and 3B).

As promoting fusion/fission inhibition with M1/Mdivi1 was observed to alter MCEC surface markers in the normothermic model, we sought to determine whether the same effects occurred in the CS-IRI model. Since we have previously shown that following CS-IRI, mitochondrial physiology and the associated immunological changes of ECs occur during the first 24 h post-reperfusion, we chose 6 and 24 h post-reperfusion as our main focus. We performed flow cytometry on a panel of surface markers and the proliferative index Ki-67 (gating strategy and live/dead staining shown in Figure S3A), and found that at 6 h post-reperfusion, VCAM-1, MHC-I, Ki-67 were significantly decreased, while PD-L1 was significantly increased. These effects were more pronounced at 24 h post-reperfusion, except that MHC-I levels returned to normal at this time point (Table 1; Figure 3C–F). There were no significant changes associated with other markers, including ICAM-1, P-selectin, CD80 (Table 1). Of note, M1/Mdivi1 pre-treatment did not impact MCEC viability, as shown by fluorescent cell counts with acridine orange/propidium iodide differential staining (Figure S3B). We further delineated PD-L1 implication in our model with PD-L1 blockade experiments using the co-culture model described above in Figure 3B, in which following reperfusion we co-incubated pretreated MCECs and allogeneic CD8+ T cells in the presence of anti-PD-L1 blocking antibodies (n = 3). (*p < .0001, **p < .005, *p < .01, *p < .05. Differences between untreated control and M1/Mdivi1-treated groups, as well as between PD-L1-unblocked control and PD-L1-blocked groups, were analyzed using Student’s t-test. In panels B and G, interferon gamma and granzyme-B levels were normalized to the number of ECs at the initiation of co-culture to account for target differences.

3.4 | Pharmacologic modulation of mitochondrial fusion/fission in ECs mitigates the alloimmune response of co-cultured T cells

Since pre-treating MCECs with M1/Mdivi1 prior to CS significantly reduced their immunogenicity to allogeneic CD8+ T cells and altered the expression of their surface markers and proliferative index, we next investigated whether changes in EC immunological phenotype could alter the T cell response. Using the CS-IRI model with pre-CS M1/Mdivi1 treatment, upon reperfusion we again co-cultured pretreated MCECs or untreated controls with pre-sensitized allogeneic CD8+ T cells. After 48 h of co-culture, we performed flow cytometry on CD8+ T cells for markers of memory phenotype, proliferative index, and intracellular cytotoxic protein production. Flow analyses showed that total populations of effector memory (CD44+ CD62L- or CD44+ CCR7) and central memory (CD44+ CD62L+) were significantly reduced in T cells co-cultured with M1/Mdivi1-pretreated MCECs compared to untreated controls (Figure 4, blue gating). Given that CD44 expression correlates to T cell activation and Tmems highly expressing CD44 (CD44hi) contribute significantly to alloimmune rejection, we gated on the CD44hi populations, and found both effector memory (CD44hi CD62L- or CD44hi CCR7) and central
memory (CD44hi CD62L+ or CD44hi CCR7+) were significantly reduced in T cells co-cultured with pretreated MCECs compared to untreated controls (Figure 4, green gating). Additionally, we noted that the proliferative index was lower in T cells co-cultured with pretreated MCECs compared to untreated controls, as indicated by Ki-67 expression (Figure 5A). Furthermore, fewer T cells producing granzyme-B and IFNγ (represented by percentage of cells) as well as less granzyme-B and IFNγ production (represented by MFI) were noted in pretreated MCEC co-cultures compared to untreated controls (Figure 5B).

### 3.5 Donor pre-treatment with M1/Mdivi1 exerts mitochondria-elongating effects on cardiac ECs but not cardiomyocytes

Our in vitro results indicated that promoting fusion/inhibiting fission in ECs altered alloimmune T cell responses. Building on these novel observations, we utilized a novel murine brain-dead donor cardiac transplant model. Donor BD was induced, and upon confirmation of donor BD, a bolus of 2.4 mg/kg M1 and 1.2 mg/kg Mdivi1 or PBS control was infused via a carotid catheter. The donor was then ventilated further for 3 h. At the end of this brain-death period, the donor heart was procured. No significant differences in blood pressure, body temperature, or heart rate where seen between the treatment or control groups. Electron microscopy on brain-dead M1/Mdivi1-pretreated donor hearts demonstrated elongated mitochondria, as compared to brain-dead untreated controls or living donor controls, only in the ECs and not in the cardiomyocytes (Figure 6A). As further validation and comparison to our in vitro studies, we isolated ECs from donor hearts and performed confocal imaging. Three-dimensional rendering demonstrated clear elongation of mitochondria in M1/Mdivi1 brain-dead donor ECs compared to controls. Quantification of these images further demonstrated significant differences between the brain-dead treated groups and the brain-dead untreated controls (Figure 6B). The effects of mitochondria elongation by M1/Mdivi1 appeared to be confined to ECs, as no mitochondrial elongation was noted in cardiomyocytes. Since our in vitro data showed M1/Mdivi1 treatment was associated with reduced EC activation, we assessed whether the treatment impacted endothelial barrier functions using in vitro trans-endothelial electrical resistance assays. We found the integrity of the endothelial monolayer pretreated with M1/Mdivi1 prior to CS was significantly improved at 18- and 24-h post-reperfusion compared to non-treated CS and normal monolayer controls (Figure S6).

### 3.6 Donor pre-treatment with mitochondrial fusion promoter/fission inhibitor protects cardiac allografts from injury and mitigates T cell alloimmune response

With our imaging studies supporting the efficacy of M1/Mdivi1 donor pre-treatment in vivo, we next determined whether the mitochondrial therapy impacted posttransplant outcomes. Brain-dead donor hearts from M1/Mdivi1-pretreated and untreated donors were heterotopically transplanted into allogeneic recipients. Forty-eight hours posttransplant, serum levels of cardiac troponin-I, a marker for cardiac injury, were found to be significantly reduced in the recipients receiving brain-dead M1/Mdivi1-pretreated hearts compared to brain-dead untreated controls (Figure 7A). Further, semi-quantitative scoring demonstrated a significant reduction in histological evidence of injury in the brain-dead M1/ Mdivi1-pretreated hearts compared to brain-dead untreated controls (Figure 7B,C). IRI is characterized by innate immune cell infiltration, and therefore, we quantified myeloperoxidase immune cell infiltrates using immunohistochemistry. In keeping with our histological injury scores, M1/Mdivi1 donor pre-treatment significantly reduced immune cell infiltration (Figure 7D).

Our in vitro data showed that M1/Mdivi1 pre-treatment reduced allogeneic T cell activity, and therefore, we next examined T cell responses in vivo. Flow cytometry analyses on CD8+ T cells isolated from allografts at 48 h posttransplant revealed that, while there were no changes in effector memory (CD44hi CD62L+) and central memory (CD44hi CD62L+) frequencies in brain-dead pretreated versus control groups (Figure 7E), there were significantly fewer T cells producing granzyme-B and IFNγ as well as less granzyme-B and IFNγ production in brain-dead pretreated compared to untreated control groups (Figure 7F). We also examined proliferative index in
FIGURE 4 Pharmacological modulation of mitochondrial fusion/fission in ECs alters the memory phenotype of co-cultured T cells. Blue gating: Flow cytometry analyses showing the percentages of both effector memory population, with phenotype CD44^+ CD62L^− (A) or CD44^+ CCR7^− (B), and central memory population, with phenotype CD44^+ CD62L^+ (B), are lower in CD8^+ T cells co-cultured with pre-cold storage M1/Mdivi1-treated MCECs versus untreated controls (n = 3). Green gating: Flow cytometry analyses with a focus on the CD44^hi populations showing that both effector memory population, with phenotype CD44^{hi} CD62L^− (A) or CD44^{hi} CCR7^− (B), and central memory population, with phenotype CD44^{hi} CD62L^+ (A) or CD44^{hi} CCR7^+ (B), are lower in CD8^+ T-cells co-cultured with pre-cold storage M1/Mdivi1-treated MCECs versus untreated controls (n = 3) (****p < .0001, ***p < .005, **p < .01, *p < .05. Differences between untreated control and M1/Mdivi1-treated groups were analyzed using Student’s t-test)
the infiltrating T cells (represented by Ki-67 expression), and surprisingly we could not detect any significant differences between groups (Figure 7G).

Furthermore, ECs were also isolated from the cardiac allografts at 48 h posttransplant, and flow cytometry analyses revealed no significant differences in surface expression of adhesion molecules,
FIGURE 6 Donor pre-treatment with M1/Mdivi1 exerts mitochondria-elongating effects on cardiac ECs but not cardiomyocytes. (A) Representative transmission electron microscopy images showing mitochondria in ECs but not in cardiomyocytes are morphologically elongated at the end of donor pre-treatment with M1/Mdivi1. (B) Representative 3D confocal images showing mitochondria in ECs isolated from M1/Mdivi1-pretreated donor hearts are elongated, and quantification of mitochondrial morphology performed as in Figure 1A (n = 3 mice/group with 50 cells/group, ***p < .0001, **p < .01. Differences between BD control and BD M1/Mdivi1 groups were analyzed using Student’s t-test)
FIGURE 7 Donor pre-treatment with mitochondrial fusion promoter/fission inhibitor protects cardiac allografts from injury and mitigates T cell alloimmune response. (A) Cardiac injury, reflected by serum cardiac troponin I levels at 48 h posttransplant, is significantly reduced in mice receiving M1/Mdivi1-pretreated allografts. (B) Histological staining and (C) quantification analysis showing significantly less cardiac injury and immune infiltration in M1/Mdivi1-pretreated allografts versus untreated controls. (D) Brain-dead donor delivery of M1/Mdivi1 significantly reduces innate immune cell infiltrates as demonstrated by myeloperoxidase immunohistochemistry in M1/Mdivi1-pretreated allografts versus untreated controls. (E) Flow cytometry analyses showing no changes in effector memory (CD44⁺ CD62L⁻) and central memory (CD44⁺ CD62L⁺) compartments of CD8⁺ T cells in M1/Mdivi1-pretreated allografts versus untreated controls. (F) CD8⁺ T cells infiltrating cardiac allografts have significantly lower granzyme-B and interferon gamma production in M1/Mdivi1-pretreated allografts compared to those infiltrating untreated controls, reflected by both frequencies of T cells producing these cytotoxic proteins and mean fluorescence intensity (MFI) of the proteins in T cells. (G) Flow cytometry analyses showing no changes in proliferative index (Ki-67) in infiltrating CD8⁺ T cells (***p < .005, *p < .05. Differences between untreated controls and M1/Mdivi1-treated groups were analyzed using Mann-Whitney test for histological analysis and Student’s t-test for the remaining analyses)
levels and elongated mitochondrial morphology in DRP1KDs, our mitochondrial dynamics toward fusion. In addition to less DRP1 protein have previously shown that modulating EC mitochondrial bioener- sion, could alter T mems responses and could potentially be clinically of EC mitochondrial physiology, such as mitochondrial fusion/fis - tion. In this study, we modulated mitochondria prior to CS and translated. In this study, we modulated mitochondria prior to CS and investigated the impact of such donor pre-treatment on immuno- logical outcomes.

Since inhibiting mitochondrial fission in the heart is protective against focal IRI, we knocked down DRP1 in ECs to skew mitochondrialdynamics toward fusion. In addition to less DRP1 protein levels and elongated mitochondrial morphology in DRP1KDsin vivo, at 48 h post-reperfusion, CD8+ T cells co-cultured with pretreated ECs display a significant reduction in both memory compartments, proliferative index, and intracellular production of cytotoxic proteins. In vivo, at 48 h posttransplant, CD8+ T cells isolated from M1/Mdivi1-pretreated allografts display a significant reduction in both memory compartments, proliferative index, and intracellular production of cytotoxic proteins. These T cells, however, do not have any changes in memory phenotype and proliferative index. The discrepancy between in vitro and in vivo T cell responses can be attributed to the complexity of the in vivo microenvironment, such as the presence of complex cytokine milieu composition.52

| Molecule name | BD control | BD pretreated |
|---------------|------------|--------------|
| VCAM-1        | 104.80 ± 10.16 | 106.60 ± 15.61 |
| P-selectin    | 215.20 ± 170.10 | 65.79 ± 11.83  |
| CD80          | 230.50 ± 75.34 | 186.10 ± 43.43 |
| MHC-I         | 83.77 ± 6.81 | 85.71 ± 17.30 |
| PD-L1         | 54.96 ± 9.40 | 62.18 ± 6.22  |
| Ki-67         | 24.79 ± 6.39 | 22.44 ± 5.46  |

costimulatory ligands, MHC-I, or coinhibitory ligands in ECs (Table 2).

3.7 Donor pre-treatment with mitochondrial fusion promoter/fission inhibitor significantly prolongs cardiac allograft survival

Finally, to assess the impact of mitochondrial therapy on allograft survival, allogeneic heterotopic transplants of Balb/c brain-dead M1/Mdivi1-pretreated hearts or brain-dead control hearts into C57BL/6 recipients were performed (illustrated in Figure 8A). Brain death has been shown to significantly reduce allograft survival compared to that from living donors. Here, M1/Mdivi1 pre-treatment of brain-dead donor hearts was associated with significant prolongation of median allograft survival (9.5 days) compared to untreated brain-dead controls (6 days, p = .0091 by log-rank test) (Figure 8B).

To determine whether M1/Mdivi1's protective effect is all mediated through an antioxidant pathway, we performed direct comparisons of M1/Mdivi1 versus NAC brain-dead donor pre-treatment. Consistent with our in vitro data (Figure S5), this protective effect was not seen with antioxidant therapy alone, as NAC pre-treatment resulted in similar outcomes to untreated controls (Figure 8B).

4 DISCUSSION

In cardiac transplantation, donor ECs play a pivotal role in allograft immunogenicity by interacting with recipient alloreactive Tmems. We have previously shown that modulating EC mitochondrial bioenergetics after reperfusion reduced their immunogenicity to allogeneic T cells. This led us to reason that modulating other aspects of EC mitochondrial physiology, such as mitochondrial fusion/fission, could alter Tmems responses and could potentially be clinically translated. In this study, we modulated mitochondria prior to CS and investigated the impact of such donor pre-treatment on immunological outcomes.

The fusion promoter M1 and the fission inhibitor Mdivi1 have been shown to effectively skew mitochondrial dynamics toward fusion when utilized in combination. In our studies, we employed them as tools to promote fusion/inhibit fission in ECs. We acknowledge a disadvantage of utilizing pharmacologic agents as mechanistic tools is the potential confounding off-target effects. However, our initial findings using the genetic knock-down model suggest that reduced EC immunogenicity is mediated specifically by skewed fusion-to-fusion.

When fusion is promoted/fission is inhibited by M1/Mdivi1 in ECs prior to pro-inflammatory cytokine-mediated activation or CS-IRI insults, their immunogenicity is reduced, evidenced by less cytotoxic proteins in co-cultures between M1/Mdivi1-pretreated ECs and allogeneic T cells, a marked reduction in VCAM-1, an important adhesion molecule for immune synapse formation and T cell adhesion, and an increase in PD-L1, a co-inhibitory ligand inhibiting T cell function. Of note, when PD-L1 is blocked, the immunoprotective effect of M1/Mdivi1 pre-treatment is abrogated at least partially, suggesting this observed effect is dependent on PD-L1 expression. PD-1, the receptor of PD-L1, has been shown to be highly expressed in certain types of functionally active Tmems and thus, M1/Mdivi1-mediated PD-L1 expression will offer significant immuno-protection against these T cell populations.

In the clinically relevant CS-IRI model, we focused on 6 and 24 h post-reperfusion because EC mitochondrial changes and immunological phenotypes are the most strongly associated at these two timepoints. T cells infiltrate cardiac allografts within the first 24 h post-reperfusion and start releasing cytotoxic proteins to mediate allograft rejection from 24-72 h post-reperfusion. In this context, a reduction of MHC-I at 6 h post-reperfusion, of VCAM-1, Ki-67 (a marker for cellular proliferative index) at 24 h post-reperfusion, and an increase of PD-L1 at 24 h post-reperfusion, as shown by our data, can alter the T cell response significantly. Indeed, in vitro, at 48 h post-reperfusion, CD8+ T cells co-cultured with pretreated ECs display a significant reduction in both memory compartments, proliferative index, and intracellular production of cytotoxic proteins. In vivo, at 48 h posttransplant, CD8+ T cells isolated from M1/Mdivi1-pretreated allografts display a significant reduction in intracellular cytotoxic protein production. These T cells, however, do not have any changes in memory phenotype and proliferative index. The discrepancy between in vitro and in vivo T cell responses can be attributed to the complexity of the in vivo microenvironment, such as the presence of complex cytokine milieu composition.

The fusion promoter M1 and the fission inhibitor Mdivi1 have been shown to effectively skew mitochondrial dynamics toward fusion when utilized in combination. In our studies, we employed them as tools to promote fusion/inhibit fission in ECs. We acknowledge a disadvantage of utilizing pharmacologic agents as mechanistic tools is the potential confounding off-target effects. However, our initial findings using the genetic knock-down model suggest that reduced EC immunogenicity is mediated specifically by skewed fusion-to-fusion.
To assess transplant outcome, we used a murine cardiac transplant model incorporating donor BD, a clinically relevant phenomenon predisposing allografts to pro-inflammatory states. We demonstrated that promoting mitochondrial fusion/inhibiting fission in donor ECs reduces cardiac injury and significantly delays allograft rejection. Of note, the effects of M1/Mdivi1 pre-treatment on cardiac allografts appear to be EC-specific, as changes in mitochondrial morphology only occurred in ECs but not in cardiomyocytes. Given our adhesion molecule expression data, we speculated that M1/Mdivi1 abrogates EC activation, which promotes improved EC barrier functions, demonstrated with our trans-endothelial resistance studies, and thus may limit exposure of cardiomyocytes to circulating M1/Mdivi1. Alternatively, given the high density of mitochondria in cardiomyocytes, a higher dose of M1/Mdivi1 may be required to mediate an effect on cardiomyocytes. Finally, the extracellular matrix separating ECs and cardiomyocytes may inhibit the diffusion of M1/Mdivi1 to the cardiomyocytes. Nevertheless, this selectivity may be a significant therapeutic benefit, and may well obviate any potentially confounding side-effects of modulating cardiomyocyte metabolic functions.

How exactly modulating mitochondrial fusion/fission alters EC immunological phenotype remains unclear. Reports by other groups have indicated mitochondrial fusion can be induced through mTOR-NFkB-OPA1 signaling. Since the NFkB pathway controls VCAM-1 expression, promoting fusion/inhibiting fission possibly induces a feedback inhibition that reduces NFkB activation, leading to reduced VCAM-1 expression. Additionally, inhibiting mTOR in human ECs has been shown to increase PD-L1, and thus the same feedback inhibition potentially leads to PD-L1 upregulation. Furthermore, in other cardiac IRI models, inhibiting mitochondrial fission in microvascular ECs leads to inhibition of mitochondrial permeability transition pore (mPTP) opening by preventing voltage-dependent anion channel-1 (VDAC-1) oligomerization. As we have shown in our previous studies that post-reperfusion mPTP inhibition reduces EC immunogenicity, M1/Mdivi1 pre-treatment prior to CS might alter VDAC-1 oligomerization in ECs, leading to longer mPTP closure post-reperfusion in our model. Future studies will be directed toward studying the exact mechanisms underlying the regulation of mitochondrial fusion/fission on EC immunological phenotype.

FIGURE 8 Donor pre-treatment with mitochondrial fusion promoter/fission inhibitor significantly prolongs cardiac allograft survival. (A) Schematics of the brain-dead murine transplant model. (B) Percent survival of transplanted cardiac allografts showing donor pre-treatment with M1/Mdivi1 after brain death leads to significantly improved survival outcomes ($n = 4$, $p = .0091$ by Mantel-Cox test), an effect that is not observed with pre-treatment of the antioxidant, N-acetylcysteine, alone.
As therapeutics could be targeted to ECs using nanoparticles containing Arginine-Glycine-Aspartate sequence, demonstrated by previous in vitro and in vivo studies, 57,58 the same delivery modality could be utilized to enhance M1/Mdivi1 uptake in ECs and would be another potential future investigation.

In summary, we demonstrate through clinically relevant in vitro CS-IRI models that promoting mitochondrial fusion/inhibiting fission in donor ECs reduces their immunogenicity and suppresses Tmem responses. We also describe a novel approach that improves transplant outcomes in vivo through modulating mitochondrial dynamics of donor cardiac allografts. These findings serve as a foundation for potential clinical translation in humans to potentially facilitate induction of transplant tolerance.

ACKNOWLEDGMENTS
The authors thank Nancy Smythe for her expertise on transmission electron microscopy and Diana Fulmer for her insights into the IMARIS software. Additionally, the murine transplant schematics were created with BioRender.com.

DISCLOSURE
The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. DTT, CA, and SNN are inventors of a filed patent on M1/Mdivi1 utilization in transplant models.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Danh T. Tran https://orcid.org/0000-0002-8200-9257

REFERENCES
1. Toyoda Y, Guy TS, Kashem A. Present status and future perspectives of heart transplantation. Circ J. 2013;77(5):1097-1110.
2. Eisen HJ. Heart transplantation in adults: Diagnosis of acute allograft rejection. In: Dardas Todd F, ed. Waltham, MA: UpToDate; 2021.
3. Libby P, Pober JS. Chronic rejection. Immunity. 2001;14(4):387-397.
4. Atkinson C, Floerchinger B, Qiao F, et al. Donor brain death accelerates acute rejection after transplantation. Am J Transplant. 2008;8(8):1652-1661. doi:10.1111/j.1600-6143.2008.02302.x
5. Epperson DE, Pober JS. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. J Immunol. 1994;153(12):5402-5412.
6. Kreisel D, Krasinskas AM, Krunick AS, et al. Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. J Immunol. 2004;173(5):3027-3034.
7. Kreisel D, Krunick AS, Balsara KR, et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol. 2002;169(11):6154-6161. doi:10.4049/jimmunol.169.11.6154
8. Kreisel D, Krunick AS, Gelman AE, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med. 2002;8(3):233-239. doi:10.1038/nm0302-233
9. Krunick AS, Kreisel D, Popma SH, et al. Mechanism of T cell-mediated endothelial apoptosis. Transplantation. 2002;74(6):871-876. doi:10.1097/00007890-200209270-00022
10. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005;5(3):465-474. doi:10.1111/j.1600-6143.2005.00759.x
11. Epperson DE, Pober JS. Antigen-presenting function of human endothelial cells directly mediate cardiac allograft rejection. Circulation. 1994;90(5):2498 (00) 00073-5
12. Kreisel D, Pratschke J, Beato F, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med. 2002;8(3):233-239. doi:10.1038/nm0302-233
13. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24 h posttransplant in naive recipients. Am J Transplant. 2008;8(8):1652-1661. doi:10.1111/j.1600-6143.2008.02302.x
14. Kreisel D, Krasinskas AM, Krunick AS, et al. Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. J Immunol. 2004;173(5):3027-3034.
15. Kreisel D, Krunick AS, Balsara KR, et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol. 2002;169(11):6154-6161. doi:10.4049/jimmunol.169.11.6154
16. Kreisel D, Krunick AS, Gelman AE, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med. 2002;8(3):233-239. doi:10.1038/nm0302-233
17. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation. 2006;82(10):1342-1351. doi:10.1097/01.tp.0000239268.64408.84
18. Ayasoufi K, Yu H, Fan R, Wang X, Williams J, Valujskikh A. Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactive memory T cells in mice. Am J Transplant. 2013;13(3):589-599. doi:10.1111/ajt.12068
19. Duboc D, Abastado P, Muffat-Joly M, et al. Evidence of mitochondrial impairment during cardiac allograft rejection. Transplantation. 1990;50(5):751-755.
20. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2983-2988. doi:10.1002/art.22085
21. Lin L, Xu HE, Bishawi M, et al. Circulating mitochondria in organ donors promote alloreactive T cell responses. JCI Insight. 2018;3(15): doi:10.1172/jci.insight.121622
22. Pollara J, Edwards RW, Lin L, Bendersky VA, Brennan TV. Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction. JCI Insight. 2018;3(15): doi:10.1172/jci.insight.121622
23. Roedder S, Sigdel T, Hsieh S-C, et al. Expression of mitochondrial-encoded genes in blood differentiate acute renal allograft rejection. Front Med. 2017;4:185. doi:10.3389/fmed.2017.00185
24. Saba H, Munusamy S, Macmillan-Crow LA. Cold preservation mediates medullary injury: involvement of mitochondrial oxidative stress. Ren Fail. 2008;30(2):125-133. doi:10.1080/08860220701813327
25. Serviddio G, Bellanti F, Sastre J, Vendemiale G, Altomare E. Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem. 2010;17(22):2325-2337. doi:10.2174/092986710791698530
26. Zepeda-Orozco D, Kong M, Scheuermann RH. Molecular profile of mitochondrial dysfunction in kidney transplant biopsies is associated with poor allograft outcome. Transplantation Proc. 2015;47(6):1675-1682. doi:10.1016/j.transproceed.2015.04.086
27. Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol. 2006;22:79-99. doi:10.1146/annurev.cellbio.22.010305.104638
28. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11(12):872-884. doi:10.1038/nrm3013

29. Parajuli N, Shrum S, Tobacyk J, Harb A, Arthur JM, MacMillan-Crow LA. Renal cold storage followed by transplantation impairs expression of key mitochondrial fission and fusion proteins. PLoS One. 2017;12(10):e0185542. doi:10.1371/journal.pone.0185542

30. Ryu SW, Han EC, Yoon J, Choi C. The mitochondrial fusion-related proteins Mfn2 and OPA1 are transcriptionally induced during differentiation of bone marrow progenitors to immature dendritic cells. Mol Cells. 2015;38(1):89-94. doi:10.14348/molcells.2015.2285

31. Buck M, O’Sullivan D, Klein Geltink R, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166(1):63-76. doi:10.1016/j.cell.2016.05.035

32. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121(18):2012-2022. doi:10.1161/circulationaha.111.906610

33. Shimizu Y, Lambert JP, Nicholson CK, et al. DJ-1 protects the heart against ischemia-reperfusion injury by regulating mitochondrial fission. J Mol Cell Cardiol. 2016;97:56-66. doi:10.1016/j.yjmcc.2016.04.008

34. Zhou H, Hu S, Jin Q, et al. Mitochondrial fission is mediated by Mff-dependent mitochondrial fission conjugation. J Biol Chem. 2017;292(16):6867-6882. doi:10.1074/jbc.M116.759643

35. Tran DT, Esckilsen S, Mulligan J, Mehrotra S, Atkinson C, Nadig SN. Mitochondrion dysregulation and HK2/VDAC1 disassociation involved mPTP opening. J Mol Cell Cardiol. 2016;97:56-66. doi:10.1016/j.yjmcc.2016.04.008

36. Zhang B, Alysandratos K-D, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Immunol. 2017;198(2):906-916. doi:10.4049/jimmunol.1601854

37. Doherty E, Perl A. Measurement of mitochondrial mass by flow cytometry during oxidative stress. J Immunol. 2017;198(2):906-916. doi:10.4049/jimmunol.1601854

38. Zhang Q, Chen Y, Fairchild RL, Heeger PS, Valujskikh A. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol. 2006;176(2):770-777. doi:10.4049/jimmunol.176.2.770

39. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, Tilney NL. Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transpl. 2000;5(4):29-35.

40. O’Malley G, Treacy O, Lynch K, et al. Stromal cell PD-L1 inhibits CD8(+) T-cell antitumor immune responses and promotes colon cancer. Cancer Immunol Res. 2018;6(11):1426-1441. doi:10.1158/2326-6066.cir-17-0443

41. Bordt EA, Clerc P, Roelofs BA, et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell. 2017;40(6):583-594.e6. doi:10.1016/j.devcel.2017.02.020

42. Mei J, Zhu J, Ding F, Bao C, Wu S. N-acetylcysteine improves early cardiac isograft function in a rat heterotopic transplantation model. Transpl Proc. 2009;41(9):3632-3636. doi:10.1016/j.transproce.2009.06.206

43. Schumann J, Stanko K, Schliesser U, Appelt C, Sawitzki B. Differences in CD44 surface expression levels and function discriminates IL-17 and IFN-gamma producing helper T cells. PLoS One. 2015;10(7):e0132479. doi:10.1371/journal.pone.0132479

44. Wang H, Zhang Z, Tian W, et al. Memory T cells mediate cardiac allograft vasculopathy and are inactivated by anti-OX40L monoclonal antibody. Cardiovasc Drugs Ther. 2014;28(2):115-122. doi:10.1007/s10557-013-6502-9

45. Mishra P, Carelli V, Manfredi G, Chan DC. Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation. Cell Metab. 2014;19(4):630-641. doi:10.1016/j.cmet.2014.03.011

46. Yao CH, Wang R, Wang Y, Kung CP, Weber JD, Patti GJ. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. eLife. 2019;8. doi:10.7554/eLife.41351

47. Wu LH, Chang HC, Ting PC, Wang DL. Laminar shear stress promotes mitochondrial homeostasis in endothelial cells. J Cell Physiol. 2018;233(6):5058-5069. doi:10.1002/jcp.26375

48. Teijeira A, Labiano S, Garasa S, et al. Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) costimulation. Cancer Immunol Res. 2018;6(7):798-811. doi:10.1158/2326-6066.cir-17-0767

49. Chakraborty S, Hu SY, Wu SH, Karmenyan A, Chiou A. The interaction affinity between vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) analyzed by quantitative FRET. PLoS One. 2015;10(3):e0121399. doi:10.1371/journal.pone.0121399

50. Blanc C, Hans S, Tran T, et al. Targeting resident memory T cells for cancer immunotherapy. Front Immunol. 2018;9:1722. doi:10.3389/fimmu.2018.01722

51. El-Sawy T, Miura M, Fairchild R. Early T cell response to allografts occurring prior to alloantigen priming up-regulates innate-mediated inflammation and graft necrosis. Am J Pathol. 2004;165(1):147-157.

52. Chen J, Liu C, Liu B, Kong D, Wen L, Gong W. Donor IL-6 deficiency evidently reduces memory T cell responses in sensitized transplant recipients. Transpl Immunol. 2018;51:66-72. doi:10.1016/j.trim.2018.09.005

53. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998;65(12):1533-1542.

54. Parra V, Verdejo HE, Iglewski M, et al. Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NFkappaB signaling pathway. Diabetes. 2014;63(1):75-88. doi:10.2337/db13-0340

55. Milstone DS, Ilyama M, Chen M, et al. Differential role of an NF-kappaB transcriptional response element in endothelial versus intimal cell VCAM-1 expression. Circ Res. 2015;117(2):166-177. doi:10.1161/circresaha.114.306666

56. Wang C, Yi T, Qin L, et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest. 2013;123(4):1677-1693. doi:10.1172/jci66204

57. Nadig SN, Dixit SK, Levey N, et al. Immunosuppressive nanotherapeutic micelles downregulate endothelial cell inflammation and immunogenicity. RSC Adv. 2015;5(54):43552-43562. doi:10.1039/c5ra04057d

58. Zhu P, Atkinson C, Dixit S, et al. Organ preservation with targeted rapamycin nanoparticles: a pre-treatment strategy preventing chronic rejection in vivo. RSC Adv. 2018;8(46):25909-25919. doi:10.1039/c8ra0555d

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.